M. Kimura

发表

SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers

K. Maeda, H. Kusuhara, Y. Sugiyama, 2007, Clinical pharmacology and therapeutics.

A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation.

Kaoru Kobayashi, K. Chiba, T. Ishizaki, 2004, Drug metabolism and pharmacokinetics.

What determines the life satisfaction of the elderly? Comparative study of residential care home and community in Japan

K. Otsuka, T. Kita, K. Saijoh, 2003 .

Clarification of the Mechanism of Clopidogrel-Mediated Drug–Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information

Kazuya Maeda, Yuichi Sugiyama, Miyuki Kimura, 2016, Drug Metabolism and Disposition.

Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers.

K. Maeda, H. Kusuhara, Y. Sugiyama, 2019, Drug metabolism and pharmacokinetics.

Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism

H. Kusuhara, Y. Sugiyama, S. Higuchi, 2008, Journal of Human Genetics.

Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose

Kazuya Maeda, Yuichi Sugiyama, Miyuki Kimura, 2012, Journal of clinical pharmacology.

Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.

K. Maeda, H. Kusuhara, Y. Sugiyama, 2017, Journal of pharmaceutical sciences.

Elucidation of N1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters

K. Maeda, H. Kusuhara, Y. Kato, 2019, Drug Metabolism and Disposition.

Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose

Kazuya Maeda, Yuichi Sugiyama, Miyuki Kimura, 2011, Pharmacogenetics and genomics.

Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects.

Y. Sugiyama, S. Higuchi, H. Takane, 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

CYP2A6 IS A PRINCIPAL ENZYME INVOLVED IN HYDROXYLATION OF 1,7-DIMETHYLXANTHINE, A MAIN CAFFEINE METABOLITE, IN HUMANS

H. Yamazaki, K. Kiyotani, T. Kamataki, 2005, Drug Metabolism and Disposition.

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

T. Matsui, T. Ishizaki, H. Furuie, 2001, Alimentary pharmacology & therapeutics.

Pharmacokinetic and bioequivalence evaluation of single‐tablet and separate‐tablet regimens for once‐daily cobicistat‐boosted elvitegravir in healthy Japanese male subjects: A randomized, two‐way crossover study

Y. Kumagai, S. Irie, Tomohiro Ishikawa, 2015, Clinical pharmacology in drug development.

Long-term evaluation of combined antihypertensive therapy with lisinopril and a thiazide diuretic in patients with essential hypertension.

T. Ishimitsu, Y. Sugishita, K. Murata, 1997, Japanese heart journal.

Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects

S. Higuchi, I. Ieiri, A. Urae, 1996 .

Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele

T. Kubota, S. Higuchi, K. Chiba, 2000, European Journal of Clinical Pharmacology.

Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function.

S. Higuchi, I. Ieiri, Daisuke Kobayashi, 2011, Drug metabolism and pharmacokinetics.

Involvement of Organic Cation Transporters in the Kinetics of Trimethylamine N-oxide.

K. Maeda, H. Kusuhara, T. Mizuno, 2017, Journal of pharmaceutical sciences.

Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status

T. Ishizaki, I. Ieiri, A. Urae, 2005, Pharmacogenetics and genomics.

Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans.

Kaoru Kobayashi, K. Chiba, T. Ishizaki, 2004, Pharmacogenetics.

P-Hydroxylation of Phenobarbital: Relationship to (s)-Mephenytoin Hydroxylation (CYP2C19) Polymorphism

S. Higuchi, N. Tashiro, I. Ieiri, 2001, Therapeutic drug monitoring.

Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.

S. Higuchi, I. Ieiri, A. Urae, 1998, Therapeutic drug monitoring.

Synthesis and electronic behaviors of alternating indium—organic moiety binary hybrid copolymer

M. Kimura, H. Matsui, Ryouichi Kudo, 2006 .

Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation

T. Kubota, I. Ieiri, S. Irie, 2018, European Journal of Clinical Pharmacology.

Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: A randomized, three-way crossover study

S. Irie, Tomohiro Ishikawa, S. Matsuki, 2014, Journal of clinical pharmacology.

Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects

Y. Sawada, H. Takanaga, S. Higuchi, 2000, Clinical pharmacology and therapeutics.

Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment

Youngjo Lee, Y. Sugiyama, Joo-Youn Cho, 2014, Pharmacogenetics and genomics.

Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

Yuichi Sugiyama, Miyuki Kimura, Hiroyuki Kusuhara, 2008, Clinical pharmacology and therapeutics.

Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein

Miyuki Kimura, Kenji Otsubo, Shun Higuchi, 2002, Clinical pharmacology and therapeutics.

Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics

Yuichi Sugiyama, Miyuki Kimura, Kenji Otsubo, 2003, Clinical pharmacology and therapeutics.

Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.

S. Higuchi, N. Tashiro, I. Ieiri, 1997, British journal of clinical pharmacology.

SCAR Markers for Practical Application of Marker-assisted Selection in Persimmon (Diospyros kaki Thunb.) Breeding

T. Akagi, K. Yonemori, N. Mitani, 2010 .

Daily expression of clock genes in whole blood cells in healthy subjects and a patient with circadian rhythm sleep disorder.

S. Higuchi, S. Ohdo, T. Jodoi, 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.

S. Higuchi, I. Ieiri, A. Urae, 1999, British journal of clinical pharmacology.

Elucidation of N 1 -methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters s

K. Maeda, H. Kusuhara, Y. Kato, 2019 .

Relationships between fat deposition in the liver and skeletal muscle and insulin sensitivity in Japanese individuals: a pilot study

Hiroaki Tanaka, E. Yoshimura, T. Tobina, 2011, Diabetes, metabolic syndrome and obesity : targets and therapy.

Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p‐Glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs

Kazuya Maeda, Yuichi Sugiyama, Miyuki Kimura, 2013, Journal of clinical pharmacology.

Effect of Curcumin on Sulfasalazine Pharmacokinetics in Healthy Volunteers

I. Ieiri, S. Irie, Takeshi Hirota, 2016 .

Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing.

Kazuya Maeda, Yuichi Sugiyama, Miyuki Kimura, 2012, International journal of clinical pharmacology and therapeutics.

Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines

I. Ieiri, Mariko Deguchi, S. Irie, 2016, Scientific Reports.

Construction and Application of Novel Spherical Alumina-Porous Carbon Composite

M. Kimura, H. Matsui, M. Yoshihara, 2005 .

Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects.

S. Higuchi, I. Ieiri, A. Urae, 1996, Clinical pharmacology and therapeutics.

Factors associated with ADL dependence: A comparative study of residential care home and community‐dwelling elderly in Japan

T. Kita, K. Saijoh, T. Wada, 2002 .

Pharmacokinetics and pharmacodynamics of FSK0808 and Gran after single intravenous drip administration or single subcutaneous administration: comparative study in healthy Japanese adult male subjects

A. Ohnishi, S. Irie, K. Matsuguma, 2015, Drug development and industrial pharmacy.